Determination of the Lowest, Safe and Effective Dose of Proellex

This study has been completed.
Information provided by (Responsible Party):
Repros Therapeutics Inc. Identifier:
First received: August 20, 2010
Last updated: June 27, 2014
Last verified: June 2014

August 20, 2010
June 27, 2014
August 2010
March 2012   (final data collection date for primary outcome measure)
Induction Amenorrhea [ Time Frame: 10 weeks ] [ Designated as safety issue: No ]
Induction of amenorrhea as determined by suppression of ovulation and/or menses, measured by using ovulation timing kits and daily diary for bleeding. Five doses will be compared in an escalating-dose, to independent groups, to a run-in placebo treatment period.
Same as current
Complete list of historical versions of study NCT01187043 on Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
Determination of the Lowest, Safe and Effective Dose of Proellex
A Single-Blind, Placebo Run-in, Phase I/II Study Comparing Five Oral Doses of Proellex®

The purpose of this study is to determine the effects of five different doses of Proellex on menses, ovulation, liver function, and steady state exposure in women of reproductive age.

A phase I/II, 5 arm, single blind study, comparing five doses of Proellex to matching placebo in healthy adult female subjects of reproductive age. Exposure to study drug will be for up to 10 weeks. In-clinic pharmacokinetic (PK) assessments will be made on the first day of dosing and on the last day (week 10). Office visits will occur every week to assess liver function and trough blood concentrations for Proellex and primary metabolite. Daily vaginal bleeding diaries will be maintained during the course of the study. A single blind run-in period of up to 56 days will begin the study to assess baseline menstrual patterns will be utilized. Twelve subjects per treatment group (total 60 subjects) will be assigned to each dose. New groups will not begin dosing until the previous dose group has completed. Daily treatments will be either 1 mg, 3 mg, 6 mg, 9 mg, 12 mg Proellex. A single blind run-in period using placebo will be incorporated to establish baseline parameters.

Phase 1
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Crossover Assignment
Masking: Single Blind (Subject)
Primary Purpose: Treatment
Drug: Proellex
1 capsule 1x/day of 1 mg(ARM1), 3 mg(ARM2), 6 mg(ARM3), 9 mg(ARM4) or 12 mg(ARM5)
Other Names:
  • Proellex
  • CDB-4124
  • Telapristone acetate
  • Experimental: ARM 1
    1 mg Proellex
    Intervention: Drug: Proellex
  • Experimental: ARM 2
    3 mg Proellex
    Intervention: Drug: Proellex
  • Experimental: ARM 3
    6 mg Proellex
    Intervention: Drug: Proellex
  • Experimental: ARM 4
    9 mg Proellex
    Intervention: Drug: Proellex
  • Experimental: ARM 5
    12 mg proellex
    Intervention: Drug: Proellex
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
March 2012
March 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Ability to understand and provide a written informed consent.
  • Healthy adult females between 18 and 50 years of age. Included in this group are women with the following conditions, not currently receiving drug treatment:

    • Excessive menstrual bleeding;
    • Menstrual pain;
    • Confirmed uterine fibroids; and
    • Confirmed endometriosis
  • Normal menstrual cycle of 26-32 days
  • Agree not to attempt to become pregnant
  • Agree to limit alcohol consumption to no more than 2 drinks per week and to avoid alcohol consumption within 48 hours of each visit
  • Ability to swallow gelatin capsules Ability to complete a daily subject diary
  • Willing to discontinue hormonal contraceptives and consent to use of double barrier contraceptive techniques over the course of the study.
  • Has a negative pregnancy test at the Screening and Baseline visits An exception for the pregnancy test requirement will be granted for subjects reporting surgical sterilization in medical history
  • A Body Mass Index (BMI) between 18 and 39 inclusive
  • Is available for all treatment and follow-up visits

Exclusion Criteria:

  • Subject is a post-menopausal woman, defined as either; six (6) months or more (immediately prior to screening visit) without a menstrual period, or prior hysterectomy and/or oophorectomy
  • Subject is pregnant or lactating or is attempting or expecting to become pregnant during the 7 month study period
  • Women with abnormal liver enzymes or liver disease.
  • Subject previously participated in Proellex clinical trials: ZPE-201, ZPU-003, ZPU-301, ZPU-302, ZPU-303, ZPU-304, ZPU-305, and ZPU-307.
  • Received an investigational drug in the 30 days prior to the screening for this study
  • Women with a history of PCOS
  • Concurrent use of any testosterone, progestin, androgen, estrogen, anabolic steroids, DHEA or hormonal products for at least 2 weeks prior to screening and during the study.
  • Use of oral contraceptives or hormone releasing IUDs in the preceding 30 days. Use of Depo-Provera® in the preceding 6 months.
  • Women currently using narcotics
  • Women currently taking cimetidine or spironolactone
  • Clinically significant abnormal findings on screening examination or any condition which in the opinion of the investigator would interfere with the participant's ability to comply with the study instructions or endanger the participant if she took part in the study
18 Years to 50 Years
Contact information is only displayed when the study is recruiting subjects
United States
Repros Therapeutics Inc.
Repros Therapeutics Inc.
Not Provided
Principal Investigator: Laura M Sterling, MD ICON Development Solutions
Repros Therapeutics Inc.
June 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP